Switzerland Cancer Research
Global Pharma Capital & CAR-T Manufacturing Hub
New Cancer Drugs
Developed in Switzerland
CAR-T Global Production
Lonza manufacturing
FDA-Approved Drugs
Roche alone
Global Pharma Capital (Roche, Novartis, Lonza)
Switzerland houses Roche, Novartis, and Lonza - developing 40%+ of world's new cancer drugs. Roche alone created 15+ FDA-approved cancer therapies including Avastin, Herceptin, and Tecentriq.
Impact:
Creating majority of world's cancer treatments
CAR-T Manufacturing Global Hub
Novartis manufactures Kymriah (first FDA-approved CAR-T) in Switzerland. Lonza produces CAR-T cells for 70%+ of global clinical trials, world's largest biomanufacturing capacity.
Impact:
Enabling global CAR-T therapy access
Proton Therapy Innovation Center
Switzerland's Paul Scherrer Institute operates world's most advanced proton therapy center, treating 1,500+ patients annually with spot-scanning precision unavailable elsewhere.
Impact:
Most precise radiation therapy globally
Antibody-Drug Conjugates Revolution
Roche pioneered antibody-drug conjugates (ADCs) like Kadcyla and Polivy, combining antibodies with chemotherapy for targeted cancer killing with 50%+ better outcomes.
Impact:
New class of targeted cancer therapy
Cancer Metabolism Drug Discovery
Swiss researchers discovered cancer cells' unique metabolic vulnerabilities, leading to 5+ FDA-approved drugs targeting cancer metabolism (IDH inhibitors, etc.).
Impact:
Starving cancer cells of fuel
Personalized Cancer Vaccine Platform
Switzerland developing next-gen mRNA cancer vaccines using same technology as COVID vaccines, showing 60%+ response rates in melanoma and lung cancer trials.
Impact:
Custom vaccines for each patient
Universal Healthcare Cancer Excellence
Switzerland achieves 70%+ 5-year cancer survival rates through mandatory universal health insurance, proving private-public healthcare hybrid delivers excellent outcomes.
Impact:
Model for hybrid healthcare systems
Clinical Trials Quality Leadership
Switzerland runs Europe's highest-quality clinical trials with 95%+ data accuracy, making it preferred location for pivotal cancer drug approval studies.
Impact:
Gold standard for clinical research
Roche Innovation Center
Basel
World's largest cancer drug developer. Created Avastin, Herceptin, Tecentriq, and 15+ FDA-approved cancer therapies. €12B+ annual R&D budget.
Key Specialties:
Novartis Institutes for BioMedical Research
Basel
Global pharmaceutical giant. Developed Kymriah (first CAR-T therapy), Gleevec (CML breakthrough), and 20+ cancer drugs. €9B+ annual R&D.
Key Specialties:
University Hospital Zurich
Zurich
Switzerland's largest hospital. Excellence in precision oncology, proton therapy, and cancer immunotherapy. 9,000+ new cancer patients annually.
Key Specialties:
Paul Scherrer Institute
Villigen
Switzerland's largest research institute. World's most advanced proton therapy center using spot-scanning technology for ultimate precision.
Key Specialties:
Switzerland welcomes international patients to cutting-edge clinical trials
Next-Generation Antibody-Drug Conjugates
Novel ADCs combining antibodies with ultra-potent chemotherapy for breast, lung, and stomach cancers showing 60%+ response rates.
Personalized mRNA Cancer Vaccines
Custom mRNA vaccines targeting each patient's unique tumor mutations for melanoma, lung, and colorectal cancers.
Ultra-Precise Proton Beam Therapy
World's most advanced spot-scanning proton therapy for brain, spine, and pediatric cancers minimizing radiation damage.
CAR-T for Solid Tumors (Novartis)
Next-generation CAR-T cells engineered to penetrate and destroy solid tumors including lung, pancreatic, and ovarian cancers.
Registry-listed trials for Switzerland currently tracked in our database, sourced from public trial registries.